The study looks at a medicine called Efruxifermin (EFX) for people with liver problems called NASH or NAFLD. NASH stands for Nonalcoholic Steatohepatitis, which is liver inflammation not caused by alcohol. NAFLD means Nonalcoholic Fatty Liver Disease, where fat builds up in the liver. This study aims to see how safe EFX is compared to a placebo (a pill with no medicine).
- The study is for adults aged 18-80 who might have NASH or NAFLD.
- Participants need a history of metabolic issues like obesity or high blood sugar.
- People with other liver diseases or unstable diabetes cannot join.
Participants will help researchers understand if EFX is safe and tolerable. This could lead to better treatments for liver issues. Keep in mind, joining a study means visits to the doctor, and there may be some risks involved. Always talk to your doctor to see if participating is right for you.